Show simple item record

SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.

dc.contributor.authorSymonds, R P
dc.contributor.authorDavidson, Susan E
dc.contributor.authorChan, S
dc.contributor.authorReed, N S
dc.contributor.authorMcMahon, T
dc.contributor.authorRai, D
dc.contributor.authorHarden, S
dc.contributor.authorPaul, J
dc.date.accessioned2012-06-15T17:39:16Z
dc.date.available2012-06-15T17:39:16Z
dc.date.issued2011-10
dc.identifier.citationSCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. 2011, 123 (1):105-9 Gynecol. Oncol.en_GB
dc.identifier.issn1095-6859
dc.identifier.pmid21723596
dc.identifier.doi10.1016/j.ygyno.2011.06.001
dc.identifier.urihttp://hdl.handle.net/10541/229168
dc.description.abstractThe aim of the study was to determine the response rate and response duration of cervical cancer previously treated by cisplatin (with or without radiation) to a combination of docetaxel and gemcitabine. Secondary endpoints were assessment of toxicity and quality of life (QoL) of patients receiving the treatment.
dc.language.isoenen
dc.rightsArchived with thanks to Gynecologic oncologyen_GB
dc.subject.meshAdult
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCisplatin
dc.subject.meshDeoxycytidine
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshNeoadjuvant Therapy
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshQuality of Life
dc.subject.meshTaxoids
dc.subject.meshUterine Cervical Neoplasms
dc.titleSCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.en
dc.typeArticleen
dc.contributor.departmentUniversity of Leicester, Department of Cancer Studies & Molecular Medicine, Leicester, UK.en_GB
dc.identifier.journalGynecologic Oncologyen_GB
html.description.abstractThe aim of the study was to determine the response rate and response duration of cervical cancer previously treated by cisplatin (with or without radiation) to a combination of docetaxel and gemcitabine. Secondary endpoints were assessment of toxicity and quality of life (QoL) of patients receiving the treatment.


Files in this item

This item appears in the following Collection(s)

Show simple item record